Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mergers & acquisitions

Brain power: fresh approaches to Alzheimer’s drug discovery

New alliances are learning from past mistakes and breaking down research barriers

- PMLiVE

Takeda’s Entyvio tops Humira in ulcerative colitis

Entyvio is important for post-merger Takeda

- PMLiVE

Shire bags US approval for constipation drug Motegrity

Approval is boost as Takeda takeover nears completion

- PMLiVE

Takeda secures investor backing for £46bn Shire takeover

The deal is expected to close early next year

- PMLiVE

Shire’s angioedema drug Takhzyro claims EU approval

Approval shortly follows a green light in the US

- PMLiVE

Shire’s angioedema drug Takhzyro recommended in Europe

Analysts expect the drug to make around $1.8bn in peak sales

- PMLiVE

Shire’s bleeding disorder drug approved in Europe

Veyvondi for patients with rare disease von Willebrand disease

- PMLiVE

Takeda rebels take aim at Shire acquisition

Shareholder group concerned about $30bn debt burden

- PMLiVE

Shire claims US okay for HAE blockbuster-in-waiting

FDA approves Takhzyro as a preventative measure for HAE attacks

- PMLiVE

Immunology keeps Shire figures solid as Takeda takeover nears

Shire’s sales increased by 6% to $3.81bn

- PMLiVE

Daily Brief: Crunch time for Brexit, GSK CEO RSVP from Trump

A round up from pharma, biotech and healthcare

- PMLiVE

Daily Brief: Keytruda and microbiome synergy, Pfizer’s files PARP contender and more

Your daily injection of pharma news

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links